Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer

Zelin Hou 1 · Yu Pan 1 · Qinglin Fei 1,2 · Yali Lin 1 · Yuanyuan Zhou 3 · Ying Liu 4 · Hongdan Guan 5 · Xunbin Yu 6 · Xianchao Lin 1 · Fengchun Lu 1 · Heguang Huang 1

Received: 10 September 2020 / Accepted: 9 November 2020 / Published online: 25 November 2020
© The Author(s) 2020

Abstract

Objective V-domain Ig suppressor of T cell activation (VISTA) is a novel immune checkpoint protein that belongs to the B7 family. The aim of this study was to investigate the prognostic significance and therapeutic potential of VISTA in patients with pancreatic cancer.

Methods Using immunohistochemistry (IHC), we examined the expression of VISTA and demonstrated the associations between the VISTA and overall survival in 223 PDAC patients from 2 different unrelated retrospective cohorts. The multiplex immunofluorescence was performed to illuminate the relationship between VISTA expression and tumor-infiltrating immune cell subclusters of PDAC. We also verified the findings in The Cancer Genome Atlas (TCGA) dataset. The anti-tumor effect of anti-VISTA therapy was studied by the mouse model with liver metastases of PDAC.

Results The VISTA protein was highly expressed in 25.6% of tumor cells (TCs), 38.1% of immune cells, and 26.0% of endothelial cells in 223 PDAC tumor tissues. VISTA expression in TCs was significantly associated with prolonged overall survival. Multiplex immunofluorescence analysis revealed that VISTA level was positively correlated with CD68+ macrophages, CD3+ T cells, and CD19+ B cells in PDAC. However, a higher expression level of VISTA was detected in tumor-infiltrating CD68+ macrophages than in CD3+ T and CD19+ B cells. Furthermore, anti-VISTA antibody treatment significantly reduced the number of metastatic nodules in livers of mouse models of PDAC with liver metastases.

Conclusion VISTA expressed in TCs is associated with a favorable prognosis in PDAC. Moreover, immunotherapy with anti-VISTA antibodies may potentially be an effective treatment strategy against PDAC.

Keywords VISTA · Immune checkpoints · Immunotherapy · Pancreatic cancer · Biomarker

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal type of human cancer, with a low 5-year survival rate of 6–10% (Yao et al. 2020). Recently, although programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blocking therapy has been used successfully in several types of malignancies (Brahmer et al. 2012; Hagi et al. 2020; Rao et al. 2020; Tomita et al. 2019), the response rate is low in PDAC patients (Brahmer et al. 2012; Tomita et al. 2019; Wainberg et al. 2020). Thus, it is imperative to investigate the mechanism of immune escape in PDAC and potential alternate therapeutic strategies.

Previous studies indicated that tumor-associated macrophages (TAMs) were abundant in the tumor microenvironment (TME) of PDAC (Chen et al. 2018; Habtezion et al. 2016; Zhu et al. 2017). Therefore, TAMs may be a useful therapeutic target against PDAC. CD47 is a signaling molecule expressed on malignant cells to suppress macrophage phagocytosis. In our previous study, we found that anti-CD47 therapy was effective in mouse models of PDAC (Pan et al. 2019b). Moreover, Blando et al. (2019) found that V-domain Ig suppressor of T cell activation (VISTA) was an immune checkpoint that was highly expressed in...
macrophages of PDAC, and revealed that VISTA may be a potential therapeutic target for this disease.

VISTA, also known as VSIR, B7-H5, PD-1H, and SISP1, belongs to the B7 family of immune checkpoint proteins, that is homologous with PD-L1 (Ni and Dong 2017; Wang et al. 2011). VISTA is mainly expressed in tumor-infiltrating immune cells (ICs) within the TME. However, in recent studies, VISTA was also detected in membranes of tumor cells (TCs), such as gastric, ovarian, and lung cancers (Boger et al. 2017; Mulati et al. 2019; Villarroel-Espindola et al. 2018; Zong et al. 2020b). VISTA expresses on T cells as a part of an inhibitory immune checkpoint that suppresses T cell activation, proliferation, and cytokine production (ElTanbouly et al. 2020; Flies et al. 2011; Lines et al. 2014). However, the biological function of VISTA is still unclear in pancreatic cancer. Specifically, the expression of VISTA in PDAC tumor tissues has not been studied comprehensively. In addition, the correlation between VISTA expression and immune cells infiltration within the TME remains uninvestigated. Finally, the anti-tumor effect of VISTA targeting therapy in PDAC has not been verified.

In this study, we performed immunohistochemistry (IHC) and multiplex quantitative immunofluorescence in two independent cohorts, and then verified the findings in The Cancer Genome Atlas (TCGA) dataset. We found that VISTA was expressed in TCs, ICs, and endothelial cells (ECs) in the TME of PDAC, and was associated with PD-L1/PD-L1 expression as well as clinical outcomes of PDAC patients. Furthermore, we demonstrated that anti-VISTA antibody treatment significantly suppressed the progression of liver metastatic tumors in mouse models of PDAC. These findings implicate VISTA as an effective prognostic factor and novel potential immunotherapeutic target for PDAC.

Materials and methods

Patients and tissue samples

The formalin-fixed, paraffin-embedded tumor samples from 223 stage I—IV PDAC patients in two cohorts were retrospectively collected. The first cohort is from Fujian Medical University Union Hospital between December 2010 and December 2018 and included 137 cases. The second cohort is from Fujian provincial hospital and included 86 cases collected between September 2005 and December 2012. All cases were verified as PDAC by histological examination. And all samples were enrolled in this study after excluding patients with neoadjuvant treatment, inflammatory diseases or active infection. The following patient characteristics were collected and evaluated. The stage of each patient was assessed based on the American Joint Committee on Cancer version 8 (AJCC 8). Informed consent had been obtained previously. The study was approved by the Committee for the Ethical Review of Research, Fujian Medical University Union Hospital.

Construction of TMAs was performed by Shanghai Outdo Biotech Company, Shanghai. In brief, a hollow needle is used to remove tissue cores as small as 1.5 mm in diameter from paraffin-embedded tumor tissues of the cohort #1. Three spots was punched out of the tumor from each cases and TMA cores with tumor and stromal contents < 5% were excluded. And the tissue cores were inserted in a paraffin block to establish an array pattern. Sections were cut from the array pattern for further study.

Immunohistochemistry (IHC)

All IHC experiments were performed in the large tissue sections, which cut from paraffin-embedded samples. Protocol of IHC was described previously (Pan et al. 2019a). The sections were deparaffinized and pretreated in 1 mmol/L EDTA at 95 °C 20 min for antigen retrieval, then incubated with 0.3% hydrogen peroxide solution for 15 min for block endogenous peroxidase activity. Primary antibodies were used to detect VISTA (CST, Clone D5L5T; 1:25) and PD-L1 (Abcam, Clone EPR19759; 1:250). For visualization, Elivision super HRP (Mouse/Rabbit) IHC Kit (KIT-9922) and DAB Kit (20×) (DAB-0031) were used follow the instructions. Counterstaining was done with hematoxylin. PD-L1 was detected in the cytoplasm/membrane of TCs, whereas VISTA was detected in the cytoplasm/membrane of TCs, ICs, and ECs.

IHC analysis of PD-L1 status were performed in our previous study (Pan et al. 2019a). VISTA expression was evaluated in TCs, ICs and ECs, respectively. Evaluation of VISTA expression in TCs and ICs were referred to previously published articles (Boger et al. 2017; Schoop et al. 2020). The VISTA expression in TCs were defined based on the intensity score as 0 for negative, 1 for weak, 2 for moderate, or 3 for strong, and the percentage of TCs stained with VISTA positive was assessed based on the score of 1–3 representing < 10%, 10–30%, and > 30% cells. The final score of each sample was calculated by adding the scores for the staining intensity and the percentage of VISTA-positive cells. TCs were considered as VISTA high expression if the score is ≥3. Ten areas of a representative field were counted at ×400 magnification for VISTA-positive ICs, and the average was calculated. High infiltration of VISTA+ ICs was defined as more than 200 positive cells on average. ECs were accessed as VISTA-high expression if any staining was present excess 5% of these cells, as described in previous study (Zong et al. 2020a, b). All specimens were evaluated by two pathologists who were blinded to the patients’ clinical information.
Multiplex immunofluorescence

Multiplex immunofluorescence was performed using a previous protocol (Gorris et al. 2018). Sections were cut from the TMAs and control tonsil tissue, and were deparaffinized, rehydrated, and then treated with EDTA buffer. 3% hydrogen peroxidase was used to block the endogenous peroxidase. Slides were incubated with the primary CD3 (Abcam, Clone PS1; 1:100), CD4 (Abcam, Clone EPR6855; 1:100), CD8 (Abcam, Clone EP1150Y; 1:500), CD19 (Abcam, Clone EPR5906; 1:500), CD68 (CST, Clone D4B9C; 1:10,000), PD-1 (Abcam, Clone NAT105; 1:25), PD-L1 (Abcam, Clone EPR19759; 1:250), VISTA (CST, Clone D5L5T; 1:25), and pan-CK (Abcam, Clone PAN-CK (Cocktail); 1:800) antibodies for 1 h at room temperature. Then, incubation with BrightVision poly-HRP-anti-Ms/Rb/Rt IgG (DPVO999HRP; Immuno-Logic) at room temperature for 10 min. Opal reagent (The Opal 7-color IHC Kit; NEL797B001KT; 1:100) for 10 min at room temperature was performed for color development. Next, epitope retrieval was performed by microwave treatment to remove the antibody complex. After dehydration, slides were counterstained with DAPI for 5 min and were enclosed with VECTASHIELD HardSet Antifade Mounting Medium (H-1400; Vector Labs). The experimental conditions and multiplex immunofluorescence panels are summarized in Supplementary Table S1.

Using each individually stained section for each reagent to establish the spectral libraries and separating the multispectral images by the inform Advanced Image Analysis software (inForm 2.4.2; PerkinElmer). Slides were scanned using the PerkinElmer Vectra slide scanner (Vectra 2.0.7 and 3.0.3; PerkinElmer). The inForm software was used to calculate the positive score. The colocalization of PD-1/PD-L1 and VISTA staining was estimated using the colocalization algorithm. The analysis was performed as previously described (Gao et al. 2017; Stack et al. 2014).

Liver metastases models

Panc02 or MPC-83 cells (1 × 10^6 cells in 50 μl PBS) were injected into the spleens of C57BL/6 or KM mice. Two weeks after the injections, the mice were randomly divided into two groups for seven per set, and treated with anti-VISTA monoclonal antibody (mAb; 200 μg/day i.p., Clone No. 13F3, BioXcell) or mouse IgG (200 μg/day i.p., Clone No. MPC-11, BioXcell). Three weeks after treatment, mice were sacrificed under deep anesthesia and the liver were harvested. Tumor metastases were quantified by counting the number of metastatic colonies on one histological section at the middle portion of each liver sample.

Cell lines and mice

The murine PDAC cell lines Panc02 and MPC-83 were obtained from Shanghai Aolu Biological Technology Co. Ltd (Shanghai, China). All cell lines were tested to rule out mycoplasma contamination.

Male C57BL/6 mice, 4 weeks of age, and male Kunming (KM) mice, 4–5 weeks of age, were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Animal study was performed at the Comparative Medicine Center of 900 Hospital of the Joint Logistics Team. Animal experiment protocols were approved by the Ethics Committee for Animal Research of 900 Hospital of the Joint Logistics Team.

Statistical analyses

Quantitative data are expressed as the mean ± standard deviation and analyzed based on variance and Student’s t tests. χ² tests were performed to compare VISTA/PD-L1 expression and clinical features. Spearman’s rank correlation was evaluated to determine the correlation between VISTA and PD-L1 expression. The differences in immunostaining among each group were analyzed by the one-way ANOVA followed by the Bonferroni multiple comparison tests. Overall survival was measured from the date of diagnosis to the day of death from any cause or the last censored follow-up. Survival analysis methods were described in our previous study (Pan et al. 2019a). Statistical significance was defined as a p value <0.05. SPSS Statistics (Version 23, SPSS) was used for statistical analysis.

TCGA data analysis

To analyze the PDAC samples from the TCGA (https://tcga-data.nci.nih.gov), we downloaded the RNA sequencing data from 177 PDAC cases. Then, the data were TPM-normalized and ENSG-ID transformed. Then, we evaluated the mRNA expressions of VISTA, CD68, CD19, CD3, CD4, CD8, PD-L1, and PD-1.

Results

Patient characteristics

The clinicopathological characteristics of 137 PDAC patients from cohort #1 and 86 PDAC patients from cohort #2 are summarized in Supplementary Table S2. In these two cohorts, the median age of patients were 62 years (35–80) and 62 years (34–83), with 35.8 and 56.4% females, and most had moderately differentiated (102 and 51 cases) or poorly differentiated (28 and 29 cases) grading. Neoadjuvant
therapy was not performed in any patients of both two cohorts. Median overall survival was 12.0 and 8.0 months.

**VISTA expression in PDAC**

Previous studies indicated that VISTA was detected frequently in the TME of several solid tumors (Deng et al. 2016; He et al. 2020; Liao et al. 2018; Rosenbaum et al. 2020). In this study, we extensively explored the expression of VISTA in 223 PDAC tumor tissues by IHC staining of each large section. The VISTA protein was detected in 99% (221/223) of all cases, and was found in TCs, ICs, and ECs. Representative IHC photomicrographs of VISTA are shown in Fig. 1.

In TCs, the percentage of positively stained cells varied from 0 to 80%, and the staining intensity ranged from weak to strong. By using the histological score (see Methods), we defined VISTA high expression in TCs as a score ≥ 3. A total of 26.3% (36/137) and 24.4% (21/86) of cases in cohort #1 and cohort #2 showed high expression of VISTA in TCs, respectively (Fig. 1a and Supplementary Table S3). This indicated that the overall number of VISTA-high TCs was low.

In ICs, the number that were VISTA-positive per field (400x) varied from 13 to 589 (median 168). Patients with less than 200 VISTA-positive ICs were classified as VISTA-low in ICs, while patients with > 200 VISTA-positive ICs were defined as VISTA-high in ICs. We found that 40.2% (55/137) and 34.9% (30/86) of cases in cohort #1 and cohort #2 were VISTA-high in ICs (Fig. 1b and Supplementary Table S3). These data revealed that tumor-infiltrating ICs showed strong expression of VISTA.

In ECs, 23.4% (32/137) and 30.2% (26/86) of cases in cohort #1 and cohort #2 were classified as VISTA-high, which was defined as positive staining in excess of 5% of all ECs (Fig. 1c and Supplementary Table S3). Altogether, these results demonstrated that VISTA was expressed comprehensively in tumor tissues of PDAC, especially in tumor-infiltrating ICs.

Notably, the expression levels of VISTA in TCs and ECs were positively correlated in both cohort #1 and cohort #2 ($r = 0.219, p = 0.01$; $r = 0.333, p = 0.002$; Supplementary Table S4), whereas the level of VISTA in ICs did not correlate with VISTA expression in TCs or ECs (Supplementary Table S4). Moreover, the levels of VISTA were barely expressed in the adjacent normal pancreas tissues (Supplementary Fig S1).

**Prognostic significance**

To explore the impact of VISTA and PD-L1 expression on clinical outcomes of PDAC patients, the Cox proportional hazards regression was performed. In cohort #1 ($N = 137$), univariate analysis showed that the variables associated with overall survival included grading [hazard ratio (HR) = 3.911, $p = 0.012$], tumor localization (HR = 0.599, $p = 0.016$), TNM stage (HR = 2.885, $p = 0.006$; HR = 4.221, $p = 0.001$; HR = 5.57, $p = 0.001$), and postoperative chemotherapy (HR = 0.488, $p = 0.001$; Table 1). Moreover, high expression of VISTA in TCs was significantly associated with a favorable overall survival (HR = 0.588, $p = 0.029$; Table 1; Fig. 2a); however, VISTA expression in ICs and ECs was not associated with survival (Table 1; Fig. 2b, c). The overall survival of patients whose TCs exhibited a low expression of PD-L1 was significantly longer than that of patients who exhibited a high expression of PD-L1 (HR = 1.759, $p = 0.022$; Table 1; Fig. 2d). Furthermore, a multivariate analysis was performed to investigate if VISTA and PD-L1 expression remained independent predictors for overall survival. VISTA expression in TCs, tumor expression of PD-L1, tumor localization, grading, TNM stage, and postoperative chemotherapy were incorporated into the multivariate analysis. The results showed that VISTA expression in TCs (HR = 0.452, $p = 0.003$), PD-L1 (HR = 2.242, $p = 0.002$), tumor localization (HR = 0.507, $p = 0.002$), grading (HR = 2.661, 1.82; p = 0.081, 0.002), TNM stage (HR = 2.858, 4.062, 6.93; p = 0.007, < 0.001, < 0.001), and postoperative chemotherapy (HR = 0.474, p = 0.001, Table 1) were independent factors for prognosis.

We further confirmed the prognostic power of VISTA on cohort #2 including 86 cases. Univariate analysis indicated that the grading, TNM stage, and postoperative chemotherapy were associated with overall survival (Table 2). Patients of VISTA high expression in TCs had long-term survivors (HR = 0.535, $p = 0.045$; Table 2; Fig. 2e), whereas VISTA expression in ICs and ECs were not correlated with survival (Table 2; Fig. 2f, g), which were similar to the results in cohort #1. PD-L1 high-expression tumors represent a short-term survivor (HR = 2.951, $p = 0.001$; Table 2; Fig. 2h). Moreover, multivariate analysis also showed that VISTA expression in TCs (HR = 0.481, $p = 0.033$), PD-L1 (HR = 3.503, $p < 0.001$), grading (HR = 2.187; p = 0.006), and TNM stage (HR = 3.119, 3.501, 3.585; p = 0.036, 0.023, 0.062; Table 2) remain prognostic markers.

**VISTA expression and the tumor immune microenvironment**

To visualize the expression landscape of VISTA in the TME of PDAC, we prepared TMAs from 137 cases of PDAC (cohort #1) using paraffin embedded tissues. With multiplex immunofluorescence, we studied the expression of multiple markers simultaneously in a single tissue section. By excluding samples with defoliation in the course of the experiment, and those with less than a 5% cancer compartment, we ultimately obtained 133 cases to study.
Fig. 1 Immunohistochemical staining of VISTA and PD-L1 in human PDAC. Human PDAC tissue samples were stained with anti-VISTA and anti-PD-L1 antibodies. Low magnification (10×) and high magnification (400×) images were obtained. Scale bar = 50 μm (red line at the bottom left). a VISTA expression in tumor cells (TCs). The red arrows indicate VISTA-positive or VISTA-negative TCs. b VISTA expression in immune cells (ICs). The red arrows indicate VISTA-positive or VISTA-negative ICs. c VISTA expression in endothelial cells (ECs). The red arrows indicate VISTA-positive or VISTA-negative ECs. d PD-L1 expression in TCs. The red arrows indicate PD-L1-positive or PD-L1-negative TCs.
Table 1 Univariate and multivariate Cox proportional analysis for overall survival (cohort #1, N=137)

|                            | n  | Univariate analysis |                       | Multivariate analysis |                       |
|-----------------------------|----|---------------------|-----------------------|-----------------------|-----------------------|
|                            |    | HR                  | 95% CI                | p value               | HR                    | 95% CI                | p value               |
| Gender                      |    |                     |                       |                       |                       |                       |                       |
| Male                        | 88 | 1                   |                       |                       |                       |                       |                       |
| Female                      | 49 | 0.884               | 0.585–1.336           | 0.558                 |                       |                       |                       |
| Age (years)                 |    |                     |                       |                       |                       |                       |                       |
| ≥ 65                        | 57 | 1                   |                       |                       |                       |                       |                       |
| < 65                        | 80 | 0.855               | 0.573–1.276           | 0.444                 |                       |                       |                       |
| Location                    |    |                     |                       |                       |                       |                       |                       |
| Head                        | 88 | 1                   |                       |                       |                       |                       |                       |
| Other                       | 49 | 0.599               | 0.394–0.911           | 0.016                 | 0.507                 | 0.327–0.786           | 0.002                 |
| Grading                     |    |                     |                       |                       |                       |                       |                       |
| G1                          | 6  | 1                   |                       |                       |                       |                       |                       |
| G2                          | 102| 1.728               | 0.628–4.755           | 0.29                  | 2.661                 | 0.887–7.981           | 0.081                 |
| G3                          | 28 | 3.911               | 1.352–11.311          | 0.012                 | 6.182                 | 1.998–19.128          | 0.002                 |
| G4a                         | 1  | –                   | –                     | –                     | –                     | –                     | –                     |
| pStage                      |    |                     |                       |                       |                       |                       |                       |
| I                           | 21 | 1                   |                       |                       |                       |                       |                       |
| II                          | 63 | 2.885               | 1.354–6.144           | 0.006                 | 2.858                 | 1.331–6.137           | 0.007                 |
| III                         | 45 | 4.221               | 1.977–9.014           | <0.001                | 4.062                 | 1.881–8.771           | <0.001                |
| IV                          | 8  | 5.57                | 2.075–14.95           | 0.001                 | 6.93                  | 2.357–20.38           | <0.001                |
| Vascular invasion           |    |                     |                       |                       |                       |                       |                       |
| Yes                         | 37 | 1                   |                       |                       |                       |                       |                       |
| No                          | 100| 1.027               | 0.66–1.596            | 0.907                 |                       |                       |                       |
| CA199 (U/ml)                |    |                     |                       |                       |                       |                       |                       |
| < 37                        | 33 | 1                   |                       |                       |                       |                       |                       |
| ≥ 37                        | 104| 1.486               | 0.928–2.378           | 0.099                 |                       |                       |                       |
| Diameter (cm)               |    |                     |                       |                       |                       |                       |                       |
| ≥ 4                         | 69 | 1                   |                       |                       |                       |                       |                       |
| < 4                         | 68 | 1.477               | 1–0.182               | 0.0503                |                       |                       |                       |
| Procedure                   |    |                     |                       |                       |                       |                       |                       |
| PD                          | 85 | 1                   |                       |                       |                       |                       |                       |
| DP                          | 43 | 0.688               | 0.446–1.061           | 0.09                  |                       |                       |                       |
| TP                          | 9  | 0.747               | 0.323–1.728           | 0.495                 |                       |                       |                       |
| Postoperative chemotherapy  |    |                     |                       |                       |                       |                       |                       |
| No                          | 57 | 1                   |                       |                       |                       |                       |                       |
| Yes                         | 80 | 0.488               | 0.324–0.734           | 0.001                 | 0.474                 | 0.312–0.722           | 0.001                 |
| VISTA in TCs                |    |                     |                       |                       |                       |                       |                       |
| Low                         | 101| 1                   |                       |                       |                       |                       |                       |
| High                        | 36 | 0.588               | 0.365–0.946           | 0.029                 | 0.452                 | 0.269–0.757           | 0.003                 |
| VISTA in ICs                |    |                     |                       |                       |                       |                       |                       |
| Low                         | 82 | 1                   |                       |                       |                       |                       |                       |
| High                        | 55 | 1.116               | 0.745–1.671           | 0.595                 |                       |                       |                       |
| VISTA in ECs                |    |                     |                       |                       |                       |                       |                       |
| Low                         | 105| 1                   |                       |                       |                       |                       |                       |
| High                        | 32 | 0.97                | 0.603–1.561           | 0.902                 |                       |                       |                       |
| PD-L1                       |    |                     |                       |                       |                       |                       |                       |
| Low                         | 107| 1                   |                       |                       |                       |                       |                       |
| High                        | 30 | 1.759               | 1.085–2.853           | 0.022                 | 2.242                 | 1.344–3.738           | 0.002                 |

HR hazard ratio, CI confidence interval, TC tumor cells, IC immune cells, ECs endothelial cells, PD pancreaticoduodenectomy, DP distal pancreatectomy, TP total pancreatectomy

*Because small number of cases in these groups, the survival analysis was meaningless.*
We applied three different panels to demonstrate the levels of VISTA in tumor-infiltrating CD68+ macrophages, CD3+ T cells, CD19+ B cells, CD4+ T-helper cells, and CD8+ cytotoxic T cells, as well as to explore the association between VISTA expression and PD-1/PD-L1 (Supplementary Table S1 and Fig S2). VISTA was detected in all investigated IC subpopulations (Fig. 3a). Moreover, VISTA was expressed at significantly higher levels in CD68+ tumor-associated macrophages than in tumor-infiltrating CD3+ T or CD19+ B cells (Fig. 3b). Furthermore, the level of VISTA in CD8+ cytotoxic cells was higher than in CD4+ helper-T lymphocytes (Fig. 3c).

We also performed a correlation analysis to explore the relationship between VISTA expression and the infiltration levels of various immune cell subclusters. VISTA expression was positively related with tumor-infiltrating CD68+ macrophages, CD3+ T cells, CD19+ B cells, CD4+ T-helper cells, and CD8+ cytotoxic T cells, as well as to explore the association between VISTA expression and PD-1/PD-L1 (Supplementary Table S1 and Fig S2). VISTA was detected in all investigated IC subpopulations (Fig. 3a). Moreover, VISTA was expressed at significantly higher levels in CD68+ tumor-associated macrophages than in tumor-infiltrating CD3+ T or CD19+ B cells (Fig. 3b). Furthermore, the level of VISTA in CD8+ cytotoxic cells was higher than in CD4+ helper-T lymphocytes (Fig. 3c).

We also performed a correlation analysis to explore the relationship between VISTA expression and the infiltration levels of various immune cell subclusters. VISTA expression was positively related with tumor-infiltrating CD68+ macrophages, CD3+ T cells, CD19+ B cells, CD4+ T-helper cells, and CD8+ cytotoxic T cells (Fig. 4a). To validate our findings, we retrieved PDAC patient data from TCGA database. As shown in Fig. 4b, the mRNA expression levels of VISTA and CD3, CD4, CD8, CD19, and CD68 were positively correlated, which was consistent with our data. Altogether, these results indicated that the VISTA expression level was associated with infiltration of ICs within PDAC and played an important role in tumor immunology.

We then analyzed the relationship between VISTA and PD-1/PD-L1 expression of PDAC. Multiplex immunofluorescence revealed a co-localized expression pattern between VISTA and PD-1 or PD-L1 in the TME of PDAC (Fig. 5a, b). We then simultaneously measured and calculated the mean fluorescent intensities of VISTA, PD-1, and PD-L1 in the overall multispectral images to investigate the correlation of these variables. The expression of VISTA was positively correlated with the expression of both PD-1 and PD-L1 (r = 0.433, p < 0.001; r = 0.238, p = 0.006, respectively; Fig. 5c, d). To confirm the association between VISTA and PD-1/PD-L1 in PDAC, we assessed their mRNA expression levels using 177 PDAC cases from TCGA database. As shown in Fig. 5e, f, the expression of VISTA was positively correlated with PD-1 and PD-L1 expression (r = 0.522, p < 0.001; r = 0.26, p < 0.001, respectively). These results indicated that VISTA expression was spatially connected with PD-1/PD-L1 expression.

The effect of anti-VISTA antibody treatment on liver metastasis of PDAC

Michaels et al. established models of pancreatic cancer liver metastasis in nude and NOD-scid-gamma mice by injecting human pancreatic cancer cells into the spleen. They found that hepatic macrophages could inhibit the progression of liver
Table 2  Univariate and multivariate Cox proportional analysis for overall survival (cohort #2, \( N=86 \))

|                      | \( n \) | HR (95% CI) | P value | HR (95% CI) | P value |
|----------------------|---------|-------------|---------|-------------|---------|
| **Gender**           |         |             |         |             |         |
| Male                 | 55      | 1           |         | 1           |         |
| Female               | 31      | 0.819       | 0.488–1.374 | 0.448     |         |
| **Age (years)**      |         |             |         |             |         |
| \( \geq 65 \)        | 36      | 1           |         |             |         |
| \( < 65 \)           | 50      | 1.241       | 0.755–2.040 | 0.396     |         |
| **Location**         |         |             |         |             |         |
| Head                 | 54      | 1           |         |             |         |
| Other                | 32      | 1.155       | 0.701–1.903 | 0.571     |         |
| **Grading**          |         |             |         |             |         |
| G1\(^a\)             | 3       | –           | –       | –           | –       |
| G2                   | 51      | 1           |         | 1           |         |
| G3                   | 29      | 2.139       | 1.272–3.596 | 0.004     | 2.187  | 1.256–3.808 | 0.006 |
| G4\(^a\)             | 3       | –           | –       | –           | –       |
| **pStage**           |         |             |         |             |         |
| I                    | 11      | 1           |         | 1           |         |
| II                   | 38      | 4.037       | 1.416–11.507 | 0.009     | 3.119  | 1.075–9.047 | 0.036 |
| III                  | 30      | 3.694       | 1.274–10.717 | 0.016     | 3.501  | 1.184–10.353 | 0.023 |
| IV                   | 7       | 5.452       | 1.524–19.497 | 0.009     | 3.585  | 0.938–13.706 | 0.062 |
| **Vascular invasion**|         |             |         |             |         |
| Yes                  | 25      | 1           |         |             |         |
| No                   | 61      | 1.349       | 0.805–2.262 | 0.256     |         |
| **Diameter (cm)**    |         |             |         |             |         |
| \( \geq 4 \)         | 26      | 1           |         |             |         |
| \( < 4 \)            | 60      | 0.836       | 0.498–1.402 | 0.497     |         |
| **Procedure**        |         |             |         |             |         |
| PD                   | 50      | 1           |         |             |         |
| DP                   | 27      | 1.149       | 0.670–1.969 | 0.613     |         |
| TP                   | 9       | 1.149       | 0.484–2.728 | 0.752     |         |
| **Postoperative chemotherapy** |         |             |         |             |         |
| No                   | 47      | 1           |         |             |         |
| Yes                  | 39      | 0.450       | 0.270–0.750 | 0.329–1.022 | 0.002  | 0.580     | 0.06  |
| **VISTA in TCs**     |         |             |         |             |         |
| Low                  | 65      | 1           |         | 1           |         |
| High                 | 21      | 0.535       | 0.290–0.987 | 0.045     | 0.481  | 0.246–0.943 | 0.033 |
| **VISTA in ICs**     |         |             |         |             |         |
| Low                  | 56      | 1           |         |             |         |
| High                 | 30      | 1.092       | 0.655–1.822 | 0.735     |         |
| **VISTA in ECs**     |         |             |         |             |         |
| Low                  | 60      | 1           |         |             |         |
| High                 | 26      | 0.983       | 0.582–1.658 | 0.948     |         |
| **PD-L1**            |         |             |         |             |         |
| Low                  | 71      | 1           |         |             |         |
| High                 | 15      | 2.951       | 1.592–5.469 | 0.001     | 3.503  | 1.799–6.821 | < 0.001 |

\( HR \) hazard ratio, \( CI \) confidence interval, \( TC \) tumor cells, \( IC \) immune cells, \( ECs \) endothelial cells, \( PD \) pancreateoduodenectomy, \( DP \) distal pancreatectomy, \( TP \) total pancreatectomy

\(^a\)Because small number of cases in these groups, the survival analysis was meaningless
micrometastasis (Michaels et al. 2018). Moreover, studies have shown that abundant resident liver macrophages and infiltrating macrophages were subsistent in liver (Ciner et al. 2020; Gul et al. 2014; Paez et al. 2012; Racanelli and Rehermann 2006). In patients with pancreatic cancer, liver metastases can occur at an early stage, which seriously affects the prognosis. In this study, we found that VISTA was highly expressed in TAMs (Fig. 3a, b). A previous study showed that VISTA could suppress T cell proliferation and anti-VISTA antibody treatment significantly prolonged the survival of tumor-bearing mice (Mulati et al. 2019). To investigate the anti-tumor effects of an anti-VISTA antibody on liver metastases of pancreatic cancer, we injected Panc02 or MPC-83 cells into the spleen of C57BL/6 or KM mice, respectively, to establish mouse models of liver metastases of PDAC. Two weeks after injection of cancer cells, the mice were divided randomly into two groups for treatment with either an anti-VISTA mAb or a control mouse IgG mAb. Three weeks after treatment, the mice were euthanized and the livers were harvested. In both the Panc02 and MPC-83 tumor models, mice receiving the anti-VISTA treatment had significantly fewer metastatic nodules in the livers compared with mice treated with IgG (Fig. 6–f). These results suggest that an anti-VISTA antibody may be a potential treatment for liver metastases of PDAC.
Discussion

VISTA is a novel immune checkpoint that is expressed predominantly within lymphoid organs and myeloid cells. It has been investigated in several tumor types. However, the role of VISTA in pancreatic cancer was unknown. Blando et al. (2019) examined tumor tissues from seven patients with pancreatic cancer and found that VISTA was expressed more frequently than PD-L1 in the tumor. Thus, VISTA may represent a new therapeutic target for pancreatic cancer. However, in their study, tumor tissue digested by enzymatic hydrolysis was used to detect VISTA expression by mass cytometry. That might alter the original characteristics of the cells and omit spatial information. In addition, the effect of anti-VISTA antibodies in PDAC has not been verified. In our study, we investigated the VISTA landscape by IHC and multiplex immunofluorescence comprehensively in large tissue sections from two different unrelated retrospective cohorts. Furthermore, we also preformed anti-VISTA antibody treatments in mouse models of pancreatic cancer with liver metastasis to verify the efficacy of this therapy in PDAC.

We found that VISTA was detectable in tumor-infiltrating CD68+ macrophages, CD3+ T cells, CD19+ B cells, CD8+ cytotoxic cells, or CD4+ helper-T lymphocytes in 137 individual human PDAC specimens. Positive correlation between the expression of VISTA and CD68, CD3, CD19, CD8, or CD4 expression in 177 human PDAC samples from TCGA database.
Fig. 5 PD-1/PD-L1 expression is colocalized and correlated with VISTA expression in PDAC. 

(a) Representative colocalization of VISTA and PD-1 proteins in PDAC specimens with immune cells detection were shown. 
(b) Representative colocalization of VISTA and PD-L1 proteins in PDAC specimens with tumor cells detection were shown. 
(c, d) Positive correlation between the level of VISTA and PD-1 or PD-L1 level in 133 human PDAC specimens. 
(e, f) Positive correlation between the expression of VISTA and PD-1 or PD-L1 expression in 177 human PDAC samples from TCGA database. Scale bar = 100 μm (white line at the bottom left)
CD4+ T-helper cells, and CD8+ cytotoxic T cells. Furthermore, VISTA was expressed at a significantly higher level in CD68+ tumor-associated macrophages. Previous studies demonstrated that the VISTA expressed in ICs could enforce the quiescence of T cells and function as a negative regulator (ElTanbouly et al. 2020; Wang et al. 2014). In addition, VISTA expression in antigen presenting cells restrained the activation of T cells, and VISTA in T cells acted as an inhibitory receptor (Ni and Dong 2017). Using a combination of single-cell RNA sequencing and single-cell ATAC sequencing technologies, ElTanbouly et al. demonstrated that genetic deletion of VISTA led to a reduction of the quiescent subset of T cells (ElTanbouly et al. 2020).

We found VISTA was also expressed in TCs and ECs of PDAC tumor tissues. In contrast, Liu et al. reported that VISTA was expressed primarily in ICs, and barely expressed in TCs of 52 PDAC tumor tissues (Liu et al. 2018). The different results about VISTA expression in TCs may be due to differences in sample sizes. Furthermore, we found that VISTA expression in TCs was significantly associated with longer overall survival. Most previous studies investigated the expression and function of VISTA in ICs, while the effect of VISTA in TCs remained unclear. Zong et al. and Zhang et al. reported that VISTA expressed in TCs was a favorable prognostic factor in patients with high-grade serous ovarian cancer and hepatoma (Zhang et al. 2018; Zong et al. 2020b). Those results were similar to our study.

Overall, the function and mechanism of VISTA expression in TCs deserve further investigation.

Both VISTA and PD-1/PD-L1 are members of the B7 family and are homologous in molecular structure. VISTA was positively correlated with PD-L1 in gastric cancer, oral squamous cell carcinoma, and epithelioid malignant pleural mesothelioma (Boger et al. 2017; Muller et al. 2020; Wu et al. 2017). In addition, co-localization and positive correlation between VISTA and PD-1/PD-L1 at the protein level were found in non-small cell lung cancer (Villarroel-Espindola et al. 2018). A previous study demonstrated that VISTA and PD-1/PD-L1 could regulate T cell activation in tumors by different pathways (Liu et al. 2015). We found that VISTA was significantly associated and co-localized with PD-L1 expression in PDAC. Our results also suggested that VISTA was positively associated with the level of T cell infiltration in the TME of PDAC, which is consistent with findings in hepatocellular carcinoma (Zhang et al. 2018). Taken together, these data suggest that VISTA and PD-1/PD-L1 may play a synergetic or cooperative role in PDAC immune evasion. However, further studies are urgently needed to explore the association between VISTA and PD-1/PD-L1 pathways in PDAC.

Immune checkpoint blockade represents an effective therapy in many advanced cancers. Recently, Mercier et al. demonstrated that VISTA mAbs could significantly suppress the growth of melanoma tumors in mouse models (Le Mercier et al. 2014). As well, Mulati et al. reported that an
anti-VISTA antibody prolonged the survival of mice with ovarian tumors (Mulati et al. 2019). Anti-VISTA therapy might interrupt the immune escape process mediated by VISTA expressed in immune cells, resulting in tumor suppression. In the current study, we demonstrated that anti-VISTA antibody treatment could significantly reduce the number of metastatic tumor nodules in mouse models of PDAC with liver metastasis. A previous study reported that combination therapy with anti-VISTA and anti-PD-L1 antibodies achieved a synergistic therapeutic effect in a murine colon cancer model (Liu et al. 2015). Although the mechanism of anti-VISTA-mediated antitumor responses remains to be further investigated, combination therapy with anti-VISTA antibodies and other drugs may be a potential treatment strategy for PDAC.

In addition, our study had several limitations. In current study, we only investigated the profile of VISTA expression in the primary tumors and its relationship to prognosis, however, lacking the situation of VISTA expression in metastatic tumors. The profile of VISTA in metastases may be different from the primary tumors.

**Conclusion**

In summary, the results of our study indicate that VISTA expression in TCs is an independent prognostic factor for PDAC patients, and expression of VISTA is associated with elevated tumor-infiltrating ICs and PD-1/PD-L1 expression. In addition, the use of anti-VISTA antibodies may be an effective therapeutic approach for PDAC.

**Author contributions** YP and HH conceived the research. YP, ZH and QF designed the methodology. YP, ZH, QF, YL, YZ, YL, HG, XY, XL and FL performed the experiments. ZH wrote the original draft of the manuscript. YP reviewed and edited the manuscript. HH supervised the study.

**Funding** This study was supported by the Medical Center of Minimally Invasive Technology of Fujian Province (No. 171, 2017 and No. 4, 2017); Joint Funds of Scientific and Technological Innovation Program of Fujian Province (2017Y9059); Joint Funds of Scientific and Technological Innovation Program of Fujian Province (2018Y9016).

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no competing interests.

**Ethical approval** Human sample collection and the study protocol were approved by the Committee for the Ethical Review of Research, Fujian Medical University Union Hospital. Animal experiment protocols were approved by the Ethics Committee for Animal Research of the Joint Logistics Team.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

Blando J et al (2019) Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci USA 116:1692–1697. https://doi.org/10.1073/pnas.1811067116

Boger C, Behrens HM, Kruger S, Rocken C (2017) The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/ PD-1: a future perspective for a combined gastric cancer therapy? Oncoimmunology 6:e1293215. https://doi.org/10.1080/2162402X.2017.1293215

Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. https://doi.org/10.1056/NEJMoa1200694

Chen S-J et al (2018) Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8. Cancer Med 7:5679–5690. https://doi.org/10.1002/cam4.1824

Ciner AT, Jones K, Muschel RJ, Brodt P (2020) The unique immune microenvironment of liver metastases: challenges and opportunities. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2020.06.003

Deng J, Le Mercier I, Kuta A, Noelle RJ (2016) A New VISTA on combination therapy for negative checkpoint regulator blockade. J Immunother Cancer 4:86. https://doi.org/10.1186/s40425-016-0190-5

ElTanbouly MA et al (2020) VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance. Science. https://doi.org/10.1126/science.aaay0524

Flies DB, Wang S, Xu H, Chen L (2011) Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol 187:1537–1541. https://doi.org/10.4049/jimmunol.1100660

Gao J et al (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551–555. https://doi.org/10.1038/nm.4308

Gorris MAJ et al (2018) Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment. J Immunol 200:347–354. https://doi.org/10.4049/jimmunol.1701262

Gul N et al (2014) Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 124:812–823. https://doi.org/10.1172/JCI66776

Habtezion A, Edderkoussi M, Pandol SJ (2016) Macrophages and pancreatic ductal adenocarcinoma. Cancer Lett 382:211–216. https://doi.org/10.1016/j.canlet.2015.11.049

Hagi T et al (2020) Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br J Cancer. https://doi.org/10.1038/s41416-020-0975-7
He XL, Zhou Y, Lu HZ, Li QX, Wang Z (2020) Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis. Sci Rep 10:2662. https://doi.org/10.1038/s41598-020-59608-w

Le Mercier I et al (2014) VISTA regulates the development of protective antitumor immunity. Cancer Res 74:1933–1944. https://doi.org/10.1158/0008-5472.CAN-13-1506

Liao H, Zhu H, Liu S, Wang H (2018) Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer. Oncol Lett 16:3465–3472. https://doi.org/10.3892/ol.2018.9059

Lines JL, Sempere LF, Broughton T, Wang L, Noelle R (2014) VISTA regulates the development of proinflammatory dendritic cells. J Exp Med 211:1841–1854. https://doi.org/10.1084/jem.20140619

Ni L, Dong C (2017) New checkpoints in cancer immunotherapy. Immunol Rev 276:52–65. https://doi.org/10.1111/imr.12524

Pace D et al (2012) Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 18:645–653. https://doi.org/10.1158/1078-0432.CCR-11-2186

Pan Y et al (2019a) Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Oncoimmunology 8:e1581529. https://doi.org/10.1080/2162402X.2019.1581529

Pan Y et al (2019b) Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. J Hematol Oncol 12:124. https://doi.org/10.1186/s13045-019-0822-6

Racanelli V, Rehermann B (2006) The liver as an immunological organ. Hepatology 43:554–62. https://doi.org/10.1080/02701539.2016.125543

Rao Q et al (2020) Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. https://doi.org/10.1007/s12072-020-10064-8

Rosenbaum SR et al (2020) FOXD3 regulates VISTA expression in melanoma. Cell Rep 30(510–524):e516. https://doi.org/10.1016/j.celrep.2019.12.036

Schoop H, Bregenzer A, Halske C, Behrens HM, Kruger S, Egberts JH, Rocken C (2020) Therapy resistance in neoadjuvantly treated gastric cancer and cancer of the gastroesophageal junction is associated with an increased expression of immune checkpoint inhibitors-comparison against a therapy naive cohort. Transl Oncol 13:165–176. https://doi.org/10.1016/j.tranon.2019.11.004

Stack EC, Wang C, Roman KA, Hoyt CC (2014) Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70:46–58. https://doi.org/10.1016/j.ymeth.2014.08.016

Tomita Y et al (2019) Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. Jpn J Clin Oncol 49:506–514. https://doi.org/10.1010/jjco.hjc026

Villarroya-Espindola F et al (2018) Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res 24:1562–1573. https://doi.org/10.1158/1078-0432.CCR-17-2542

WainbergZA et al (2020) Open-label, Phase 1 study of Nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-0099

Wang L et al (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208:577–592. https://doi.org/10.1084/jem.20100619

Wang L et al (2014) Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc Natl Acad Sci USA 111:14846–14851. https://doi.org/10.1073/pnas.1407447111

Wu L et al (2017) Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother 66:627–636. https://doi.org/10.1007/s00262-017-1968-0

Yao W, Maitra A, Ying H (2020) Recent insights into the biology of pancreatic cancer. EBioMedicine 53:102655. https://doi.org/10.1016/j.ebiomed.2020.102655

Zhang M, Pang HJ, Zhao W, Li YF, Yan LX, Dong ZY, He XF (2018) VISTA expression associated with CD8 confines a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer 18:511. https://doi.org/10.1186/s12885-018-4435-1

Zhu Y et al (2017) Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47(323–338):e326. https://doi.org/10.1016/j.immuni.2017.07.014

Zong L, Mo S, Yu S, Zhou Y, Zhang M, Chen J, Xiang Y (2020) Expression of the immune checkpoint VISTA in breast cancer. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-020-02554-3

Zong L, Zhou Y, Zhang M, Chen J, Xiang Y (2020) VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother 69:33–42. https://doi.org/10.1007/s00262-019-02434-5

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Affiliations

Zelin Hou¹ · Yu Pan¹ · Qinglin Fei¹,² · Yali Lin¹ · Yuanyuan Zhou³ · Ying Liu⁴ · Hongdan Guan⁵ · Xunbin Yu⁶ · Xianchao Lin¹ · Fengchun Lu¹ · Heguang Huang¹

Zelin Hou
HouZeLin2@163.com

Yu Pan
yupan199002@163.com

Qinglin Fei
cocoa9th@gmail.com

Yali Lin
358879706@qq.com

Yuanyuan Zhou
yuanyuanzhou05@163.com

Ying Liu
269299498@qq.com

Hongdan Guan
2199397357@qq.com

Xunbin Yu
276204404@qq.com

Xianchao Lin
linxc07@163.com

Fengchun Lu
fengchun160@163.com

¹ Department of General Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, People’s Republic of China

² The Cancer Center, Fujian Medical University Union Hospital, Fuzhou 350001, China

³ Department of Geriatrics, Fujian Medical University Union Hospital, Fuzhou 350001, China

⁴ Department of Endocrinology, Quanzhou Hospital of Traditional Chinese Medicine, Quanzhou 362000, China

⁵ Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, China

⁶ Department of Pathology, Fujian Provincial Hospital, Fuzhou 350001, China